Serum level assessment of serum level of Neopterin (NP) and Anti-Cyclic Citrullinated Peptide (ACCPA) Antibody as markers of disease severity in rheumatoid arthritis Husein Mortadha Mohammed1,*, Mansoor Ali2 1Medical Microbiology, Faculty of Medicine, University of Kerbala, Iraq 2Clinical Immunology, Faculty of Medicine, University of Kerbala, Iraq *Corresponding author: Mortadha Mohammed Husein. Medical microbiology, Faculty of Medicine, University of Kerbala, Iraq. E-mail: sharifimortadha0@gmail.com
Online published on 15 March, 2019. Abstract Rheumatoid arthritis is a chronic systemic autoimmune inflammatory disease characterized by synovitis and joint and cartilage destruction. Rheumatoid arthritis occurs when the immune system works incorrectly. This study aims to estimate the neopterin and anti-cyclic citrullinated peptide antibody as immunological markers that associated with the disease activity treatment response. The methodology of the study is conducted by the case-control study design. The test group consisted of 124 patients with rheumatoid arthritis. Control group that numbered (50). Serum neopterin and (ACCPA) concentrations were measured by Enzyme immunoassay. Statistical analyses were applied to analyze the research data. The results have shown the mean level of NP and ACCPA in the patient's group, there is a highly significant difference in the disease activity. The main findings of this study, the neopterin and anti-cyclic citrullinated peptide antibody had significant differences with the severity of the disease which may be useful as immunological markers for the disease activity and monitoring of response to treatment. Top Keywords Rheumatoid arthritis, neopterin, risk factors, Immunopathogenesis. Top |